HC Wainwright Predicts Scholar Rock FY2030 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Scholar Rock in a research note issued on Monday, January 26th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of $1.07 per share for the year. HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share.

A number of other brokerages have also recently commented on SRRK. Wolfe Research assumed coverage on Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price on the stock. Truist Financial dropped their price objective on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, October 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Citigroup initiated coverage on shares of Scholar Rock in a research report on Friday, January 9th. They set a “buy” rating and a $55.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $51.14.

Scholar Rock Stock Performance

SRRK opened at $44.89 on Tuesday. Scholar Rock has a 1-year low of $22.71 and a 1-year high of $48.28. The stock has a market cap of $4.58 billion, a P/E ratio of -14.25 and a beta of 0.63. The stock’s 50 day simple moving average is $43.89 and its 200 day simple moving average is $37.37. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same period last year, the business posted ($0.66) EPS.

Insider Buying and Selling at Scholar Rock

In related news, CFO Vikas Sinha sold 16,755 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the sale, the chief financial officer directly owned 583,245 shares in the company, valued at approximately $24,904,561.50. This represents a 2.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $2,453,115.00. Following the transaction, the chief executive officer owned 1,541,645 shares in the company, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 305,687 shares of company stock worth $13,540,573. Corporate insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

A number of hedge funds have recently made changes to their positions in SRRK. Three Seasons Wealth LLC grew its holdings in shares of Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock valued at $483,000 after purchasing an additional 222 shares during the last quarter. Principal Financial Group Inc. boosted its position in Scholar Rock by 7.9% during the 3rd quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock valued at $231,000 after purchasing an additional 456 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Scholar Rock by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock worth $130,000 after buying an additional 500 shares during the last quarter. California State Teachers Retirement System increased its position in Scholar Rock by 0.9% in the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after buying an additional 577 shares during the period. Finally, Tema Etfs LLC lifted its stake in Scholar Rock by 6.6% in the fourth quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after buying an additional 616 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).